Your Health, We Care

Home > Photo Wall > Honor and qualification

Production Approval for Adagrasib

Release date: 2024-07-09 15:44:48     Recommended: 93

02L1070_24 阿达格拉西布 批文_00.jpg

Adaglacib is a specific oral inhibitor targeting the KRAS G12C mutant, suitable for adult patients with specific lung diseases who have been approved by FDA for testing, confirmed to have KRAS G12C mutations, and have received at least one systemic treatment. Adaglacib inhibits the activity of KRAS G12C mutant proteins, thereby preventing malignant cell proliferation and metastasis.

Company News

Research News

Drug news